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Abstract The development of novel drugs for the treatment of chronic obstructive pulmonary disease (COPD) poses 
significant challenges.The mechanisms through which the chronic symptoms of COPD arise are poorly understood, making 
identification of potential therapeutic targets and in vivo evaluation of potential therapies extremely difficult. Despite these 
challenges, a unique approach of combined D2dopamine, 132-adrenoceptor agonism was identified as a valid potential 
target for the treatment of key COPD symptoms, the therapeutic potential of which was investigated in a series of pre- 
clinical evaluations. Subsequent clinical assessment has amassed a wealth of data from over 4000 patients, providing 
valuable insights into COPD, clinical trial design and the value of patient self-assessment tools. 
© 2003 Elsevier Science Ltd 
TACKL ING A CHRONIC  PROBLEM 
While no drug can halt the progression of chronic 
obstructive pulmonary disease (COPD), patients 
currently rely on a combination of bronchodilators and 
anti-inflammatory agents to manage their disease (I,2). 
Drugs approved for this indication were, however, 
originally developed for the treatment of asthma, despite 
the differing aetiology and pathophysiology of the two 
conditions. Due to decades of research in asthmatic 
patients, bronchodilators are now available that can 
afford patients with COPD some degree of relief. In a 
disease characterized by limited airway reversibility, 
however, this approach can only be met with limited 
success. With increasing recognition of the need to 
address a range of key symptoms (3), it is evident that 
specific therapy tailored to treat a spectrum of COPD 
symptoms is urgently required. Recognition of this 
outstanding need has led to considerable research 
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efforts in recent years and a number of potential new 
therapies have been investigated. 
IDENT IF ICAT ION AND ASSESSMENT 
OF NOVEL AGENTS 
The mechanisms through which the chronic symptoms 
of COPD arise remain poorly understood, making 
identification of therapeutic targets extremely difficult. 
Despite this challenge, efforts to identify novel solutions 
have been intense. Dopamine is a peripheral neuro- 
transmitter that can modulate the activity of sensory 
nerves.This raises the possibility of inhibiting the sensory 
nerves in the lung, thought to be responsible for reflex- 
induced COPD symptoms (4). Dopamine agonism was 
therefore identified as a potential target for the 
treatment of key COPD symptoms. 
Sibenadet HCI (Viozan TM, AR-C68397AA) is the first 
of a new class of dual D 2 dopamine receptor, 132-adreno- 
ceptor agonists.This novel agent represents the first drug 
engineered specifically to combine the benefits of 
conventional 132-adrenoceptor agonism with the sensory 
modulatory effects of a dopamine agonist in a single 
agent. It is now known that the potential of this 
therapeutic approach did not translate into sustainable 
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clinical efficacy (5). Although initial benefit appeared 
positive, a reduction in efficacy over time was apparent. 
Tachyphylaxis to ~2-agonists has not been previously 
documented in COPD, but in these studies this 
phenomenon may have occurred due to potency of the 
compound, as a result of the unique properties of 
sibenadet or other unidentified issues. The relatively late 
onset of tachyphylaxis may be due in part to the 
particular endpoints studied in the trials and their 
sensitivity to highlighting a developing tolerance to the 
compound. Despite these disappointing results, however, 
a great deal of important information and key findings 
have arisen from the sibenadet development programme. 
Investigation of the hypothesis that stimulation of 
D2-receptors on sensory nerve endings in the airways 
would inhibit afferent activity and consequently suppress 
key COPD symptoms (breathlessness, cough and 
sputum) was hampered by a lack of satisfactory animal 
models of COPD. New experimental paradigms were 
therefore required in order to test this idea. The 
Dzagonist properties of sibenadet were extensively 
evaluated in a comprehensive programme of in vitro and 
in vivo investigations, which confirmed the ability of 
sibenadet o inhibit reflex tachypnoea, cough and mucus 
(4). Most recently, the presence of D 2 dopamine 
receptors on the sensory neurons of thoracic dorsal 
root ganglia has been demonstrated, strengthening the 
theoretical value of dopamine agonism in respiratory 
disease (6). 
Despite this substantial body of technically demanding 
work, in vivo studies may not predict the human 
experience. Therefore, these data could only be 
interpreted as providing an indication of the potential 
clinical effect of sibenadet. Studies of the clinical 
pharmacology of sibenadet were thwarted by the lack of 
an inhaled dopaminergic antagonist suitable for use in 
humans and these data were therefore not available to 
guide clinical investigation of sibenadet in the patient 
population. 
CHALLENGES IN  THE CL IN ICAL  
EVALUATION OF S IBENADET AND 
LESSONS LEARNED 
Assessing new treatments in COPD can be as fraught 
with difficulty as the preceding pharmacological studies. 
Crucial to any clinical trial is the selection of the correct 
endpoint. Clinical evaluation of sibenadet assessed three 
major parameters, key COPD symptoms, lung function 
and adverse events. Some novel approaches were 
developed in order to address specific needs within the 
development programme. 
Spirometry is commonly used for testing and 
quantifying pulmonary function, with FEV I the most 
often utilized measurement o assess the effect of an 
intervention on airway obstruction. Reliance on FEV I 
measurements tems from routine use in patients with 
asthma, where this measure is used to demonstrate 
improvement in clinical trials. However, ~lthough this 
measurement is widely used in clinical trials of COPD 
therapy, it may be less useful for predicting patient 
improvement, as patients with COPD by definition have 
limited reversibility of airway function. In addition, there 
is no evidence to suggest that the change in FEV~ with 
treatment necessarily parallels changes in perception of 
COPD symptoms. Adequate evaluation of the benefits 
of a dual D2/~2-agonist required a shift in focus from 
reliance on FEV I as the sole measure of efficacy to 
incorporating a novel approach to assessing symptomatic 
benefit. As no widely accepted assessment approach 
existed, a new instrument hat was simple and easy to 
use was required.The Breathlessness, Cough and Sputum 
Scale (BCSS) was therefore developed. 
ASSESSMENT OF  KEY SYMPTOMS - 
THE BREATHLESSNESS,  COUGH 
AND SPUTUM SCALE 
This patient-reported outcome approach was designed 
to meet a specific need, i.e. to assess change in patient 
symptoms on a daily basis in response to therapy. It was 
used in Phase II clinical evaluations and the reliability, 
reproducibility and validity of this approach was 
subsequently established (6). The BCSS was therefore 
able to identify early clinical potential and subsequently 
provided clear conclusions regarding long-term efficacy 
in Phase III evaluations.The co-primary endpoint selected 
for large-scale clinical investigation was change in BCSS 
total score from baseline to the final 4 weeks of treat- 
ment.This distinction was considered important in order 
to detect a continuing effect in patients with a chronic 
disease such as COPD.The necessity for this approach 
was highlighted by the study results, as the large changes 
in patient symptoms seen at the start of the study would 
have influenced the study outcome had the whole 
treatment period been used as the primary endpoint (5). 
It was, however, considered important to collect data 
throughout the study period in order to describe 
ongoing changes and to enable demonstration of patient 
progression or deterioration. 
Statistical analyses have demonstrated a correlation 
between patient and physician opinion of efficacy, change 
in HRQL (as determined by the SGRQ) and BCSS scores 
(7).These analyses have therefore enabled interpretation 
of a clinically meaningful change in BCSS total score and 
established the BCSS as a potentially valuable tool for 
assessing symptomatic benefit of treatment. This scale 
may also provide a valuable aid to diagnosis when used in 
combination with spirometric assessments; as indicated 
in the GOLD guidelines, chronic cough and mucus are 
often overlooked as diagnostic symptoms (3). Use of the 
BCSS in patients at high risk of developing COPD (such 
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as long-term smokers) in order to determine the degree 
of symptomatology present might act as an indicator that 
further patient evaluation is required.The BCSS also has 
potential application as an aid to treatment decision- 
making as it acts as an ongoing summary of the patient's 
condition. Further assessment and validation for these 
applications would, however, be required. 
A possible additional value of the BCSS became 
evident through sub-analysis of study data as the total 
score appeared to be predictive of an exacerbation event 
in the subset of patients who had experienced an 
exacerbation (7). Mean BCSS scores begin to increase 
some days prior to an exacerbation and are able to track 
progress to resolution. Further investigations need to be 
conducted to investigate what is, as yet, only a 
hypothesis. In particular, determination of both the 
sensitivity and specificity of using changes in BCSS total 
scores to predict an exacerbation is required. 
Exacerbations and their treatment are still poorly 
understood, but the ability to track symptom changes, 
with a view to earlier recognition and intervention, may 
decrease overall costs by reducing the need for 
hospitalizations or emergency room (ER) visits. A 
greater understanding of exacerbations in general would 
be of considerable value and investigation of the role of 
gender differences, disease subtype, disease severity, 
exacerbation severity and individual symptoms driving an 
exacerbation is warranted in future clinical studies. 
STUDY DESIGN 
Being the first of a novel class of agents, determining 
optimal trial design for early clinical evaluation of 
sibenadet posed particular problems.While the Phase II 
programme achieved the objectives of demonstrating 
proof of concept and dose-relationship with sibenadet 
treatment, the promising results demonstrated in these 
early clinical evaluations were not sustained over the 
course of the longer-term studies (5,8). It is now clear 
that Phase ll studies of longer duration would have 
provided greater information on the clinical potential of 
sibenadet. The disappointing results obtained from 
Phase III evaluation of sibenadet could not have been fully 
anticipated from the 6-week Phase II study, highlighting 
the fact that a study duration typical for assessment of 
asthmatic patients is not necessarily appropriate for the 
COPD scenario. This is, of course, dependent on the 
objective of the study. For instance, assessment of 
changes in HRQL may require a longer investigation 
period than assessment of short-term changes in lung 
function. Although no surrogate markers of treatment 
effect have yet been defined in patients with COPD, 
successful identification of such markers would 
represent a significant advance, thereby allowing effective 
identification of early clinical potential and avoiding 
unnecessary burden on patients. 
Interpretation of the sibenadet Phaselll data was 
complicated by the marked improvements in BCSS and 
SGRQ scores amongst patients receiving placebo (5). 
This effect may be explained by the well-known positive 
response of many patients, irrespective of therapy, to the 
increased levels of care experienced uring participation 
in a clinical trial (9). In addition, when recruiting patients 
with symptoms or frequent exacerbations, it is possible 
that a proportion of the study population will be 
recovering from an exacerbation during the study and 
over time will demonstrate improvement. Patients may 
take many weeks, or even months, to recover fully from 
an exacerbation and therefore, despite carefully defined 
exclusion criteria, this potential problem is a feature of 
the COPD population that will need to be considered in 
all future studies. Although the recruitment require- 
ments and randomization procedures should ensure that 
the effects of ongoing exacerbations are equal in both 
treatment groups, additional steps could be taken to limit 
this possibility. Exclusion criteria could be tightened (e.g. 
by excluding patients who have had an exacerbation 
within the previous 3 months), but this may impact on 
patient recruitment and would not necessarily ensure 
patients were in a stable condition. A longer baseline 
period could be considered, but the benefits must be 
weighed against the practical disadvantages. This 
approach may also raise ethical issues by requiring 
patients to be off some of their usual medications for a 
longer period than usual, which could actually induce an 
exacerbation. 
LUNG FUNCTION 
With increasing recognition of the need to manage key 
COPD symptoms and to identify therapeutic approaches 
other than simple bronchodilation, it is apparent that 
reliance on FEV I as the most relevant measure for 
determining therapeutic benefit in COPD requires 
reassessment. In the case of sibenadet, the BCSS 
provided important additional information regarding 
long-term clinical efficacy. As assessment of forced 
expiratory volume in one second (FEVI) is a widely 
recognized and accepted study endpoint, it may not be 
possible (or advisable) to move away from this approach 
entirely, but rather to recognize its limitations and 
consider additional efficacy assessments.The complexity 
of this chronic disease may, however, necessitate the use 
of multiple endpoints in order to determine the value of 
future therapeutic strategies adequately. 
CONCLUSIONS 
What then have we learned during the development 
programme for sibenadet? It is apparent that novel 
pharmacological models offer insight into disease 
mechanisms but their translation to the bedside is 
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complex and can be disappointing. Confirmation that the 
desired mechanism operates in man greatly enhances 
their utility. Manipulation of the re!ative potency of the 
constituents of a molecule with dual activity (or a 
combination drug regimen) may modify the desired 
outcome. The relatively high potency of the ~2-agonist 
component of sibenadet is an interesting candidate to 
explain the surprisingly rapid loss of effect in the longer 
studies that mirrored the previously observed time 
course of therapy in their first 6weeks. Such an 
explanation can, however, only be speculative at this time. 
Symptoms can, and should, be quantified. The 
development of the BCSS illustrates how a relatively 
simple scale, using data that can be easily collected, can 
provide important clinical insights.The potential for using 
this approach in developing patient self-management 
plans is therefore apparent. By using symptom-based 
scales, such as the BCSS, the timecourse of 
exacerbations can be monitored and changes similar to 
those seen in more carefully controlled clinical cohort 
studies can be replicated (10). This has great potential 
for improving our understanding of these crucial events, 
but would require considerable investigation and 
definition before any clinical application could be 
realized. 
The time course of most clinical events in COPD is 
slower than those of asthma.This does not simply apply 
to changes in pulmonary function, but is even more 
important when endpoints downstream from the purely 
physiologic are considered.Thus changes in health status 
reflect, in part, sustained changes in the intensity and 
frequency of the symptoms patients experience. 
Likewise, exacerbations must have a chance not to occur 
before their absence is slowly registered as an 
improvement in wellbeing. Having demonstrated proof of 
concept, clinical studies of new treatments would be best 
advised to adopt an assessment period of at least 
12 weeks to capture some of these effects on wellbeing 
or exacerbations before committing patients, doctors 
and sponsors to longer and more taxing studies. The 
study period would, however, be largely dependent on 
the mechanism of drug action and anticipated outcomes. 
Despite disappointing efficacy results, the development 
of sibenadet has provided additional information on drug 
design and evaluation that will prove a valuable resource 
for future investigation in this field. The creative 
solutions developed to address each challenge may pave 
the way for future agents, with the hope that better 
solutions can be found to improve therapeutic options 
for patients with COPD. 
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